EHC files 8-K — Item 2.02 Results of Operations

What Was Filed

Encompass Health (EHC) filed an 8-K with the SEC on April 30, 2026 at 16:24:06, disclosing Item 2.02 (Results of Operations and Financial Condition), per the SEC’s plain-language filing definitions. The EDGAR-linked filing references an attached earnings release at https://www.sec.gov/Archives/edgar/data/785161/000078516126000128/ehcearningsrelease33126.htm. The company has a $9.9B market capitalization.

The Disclosure

Item 2.02 filings for publicly traded healthcare providers typically include preliminary quarterly operating results, key financial metrics, and a high-level overview of segment performance. For EHC, this filing covers first-quarter 2026 results, as confirmed by the company’s tracked earnings history. Unlike comprehensive 10-Q submissions, Item 2.02 filings are abbreviated, focusing on top-line and bottom-line results rather than full balance sheet or cash flow statements. No additional SEC items were included in this 8-K, per public filing metadata.

Cross-Reference to Prior Signals

This earnings release follows two weeks after a series of Form 4 insider transactions filed April 16, 2026, involving seven of EHC’s board members. Two directors received compensatory stock awards at prevailing market rates ahead of the April 30 results: Edward M. Christie III was granted 261 shares at $106.17 for a total value of $27,710, and Christopher R. Reidy was granted 334 shares at $106.48 for a total value of $35,564. The remaining five directors received zero-cost equity awards. The April 30 results included a 19% EPS beat (1.8 vs consensus estimate 1.51) and a 1.2% revenue beat ($1.5866B vs estimated $1.5677B), per provided earnings history. Analyst ratings have remained static since February 1, 2026, with 1 Strong Buy and 11 Buy ratings, no Hold, Sell, or Strong Sell scores. As of December 31, 2025, EHC had 593 institutional holders owning 97.4% of its float, with 78 new positions initiated and 252 increased in Q4 2025.

What This Filing Does NOT Tell Us

First, the abbreviated Item 2.02 filing does not include detailed segment-level operating margins for EHC’s two core segments: Inpatient Rehabilitation and Home Health and Hospice, which are critical valuation metrics for post-acute healthcare providers. Second, the filing does not contain full quarterly financial statements (balance sheet, statement of cash flows) as these are reserved for 10-Q submissions, not Item 2.02 8-Ks. Third, the filing does not confirm whether forward-looking guidance (such as adjusted EBITDA targets or full-year 2026 outlook) was included in the referenced earnings release, as this detail is not disclosed in the 8-K’s public metadata.